The three G-protein-coupled cannabinoid receptor subtypes currently recognized are central (CB1), peripheral (CB2), and GPR55. The majority of CB1 receptors are found at central and peripheral nerve terminals. CB2 receptors are mainly found in immune cells and non-neuronal tissues where they regulate cytokine release and cell migration. According to recent reports, the CNS may also express CB2 receptors. Non-CB1/CB2 receptors known as GPR55 show affinity for endogenous, botanical, and synthetic cannabinoids. Anandamide and 2-arachidonylglycerol are examples of endogenous ligands for cannabinoid receptors.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V71558 | CB1 agonist 1 | 851212-80-1 | CB1 agonist 1 (compound 22) is a CB1 agonist. |
|
V71601 | CB1 inverse agonist 2 | 1019839-52-1 | CB1 inverse agonist 2 is an orally bioavailable cannabinoid receptor CB1 inverse agonist. |
|
V3101 | CB1-IN-1 (DBPR211) | 1429239-98-4 | CB1-IN-1 (also known as DBPR211) is a novel, potent, peripherally restricted antagonist of the CB1R (cannabinoid 1 receptor) with Ki values of 0.3 nM and 21 nM for CB1R (EC50 of 3 nM) and CB2R, respectively. |
|
V78669 | CB2 PET Radioligand 1 | CB2 PET Radioligand 1 (compound [18F]9) is a PET Radioligand directed against hCB2 (Ki=7.7 nM). | |
|
V71605 | CB2 receptor agonist 2 | 1314230-75-5 | CB2 receptor agonist 2 is a potent and specific agonist of the CB2 receptor. |
|
V78091 | CB2 receptor antagonist 3 | CB2 receptor antagonist 3 (compound (S)-1) is an inverse agonist of the cannabinoid receptor CB2R with Kd=39 nM. | |
|
V71606 | CB2R agonist 1 | 1817633-49-0 | CB2R agonist 1 is a selective ligand for cannabinoid receptor subtype 2 (CB2R) with EC50 of 0.56 µM. |
|
V78671 | CB2R agonist 2 | CB2R agonist 2(compound cis-17-para) is a CB2R agonist. | |
|
V79877 | CB2R agonist 3 | CB2R agonist 3 is an agonist of cannabinoid receptor 2 (CB2R) with EC50 of 0.37μM and plays an important role in the immune system. | |
|
V71603 | CB2R PAM | 2244579-87-9 | CB2R PAM is an orally bioactive PAM (positive allosteric modulator) of cannabinoid type 2 receptors (CB2Rs). |
|
V78672 | CB2R-IN-3 | CB2R-IN-3 is a selective antagonist of cannabinoid type 2 receptors (CB2R). | |
|
V79376 | D1R antagonist 1 | D1R antagonist 1 (compound 12a) is a D1R antagonist involved in G-protein and β-arrestin-based signaling. | |
|
V78584 | D3R ligand 1 | D3R ligand 1 (compound 23b) is a potent and specific ligand for the dopamine receptor D3R (Ki=66 nM), containing the THPB template. | |
|
V78108 | Dopamine D3 receptor antagonist-1 | Dopamine D3 receptor antagonist-1 is a dopamine D3 receptor selective or multi-target ligand (Ki = 1.58 nM) that may have effects on central nervous system/CNS diseases. | |
|
V79195 | Dopamine D3 receptor antagonist-2 | Dopamine D3 receptor antagonist-2 is a dopamine D3 receptor selective (Ki = 2.16 nM) or multi-target dual ligand that may have an effect on central nervous system/CNS diseases. | |
|
V71591 | Eicosapentaenoyl ethanolamide | 109001-03-8 | Eicosapentaenoyl ethanolamide is an omega-3 fatty acid, an N-acylethanolamine (NAE). |
|
V71562 | Eicosapentaenoyl ethanolamide-d4 | 946524-41-0 | Eicosapentaenoyl ethanolamide-d4 is the deuterated form of Eicosapentaenoyl ethanolamide. |
|
V71576 | Epifriedelanol acetate | 2259-07-6 | Epifriedelanol acetate (Compound IIIc) is a naturally occurring compound. |
|
V77951 | FGH31 | FGH31 (Compound 24) is a potent and specific GRK2-dependent dopamine D4 agonist/activator with a Ki of 1.6 nM. | |
|
V77010 | Fluphenazine-d8 dihydrochloride (fluphenazine d8 dihydrochloride) | Fluphenazine-d8 (di-HCl) is the deuterium labelled form of Fluphenazine di-HCl. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
